General

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by riva… [Read Full Story on CNBC →](https://www.cnbc.com/2026/09/21/lilly-is-ramping-up-future-manufacturing-for-foundayo-obesity-pill.html)